Co-Diagnostics Submits Co-Dx PCR Flu A/B & RSV Test for FDA Clearance
Co-Diagnostics submitted a dual 510(k) premarket notification and CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV multiplex respiratory test.
Co-Diagnostics submitted a dual 510(k) premarket notification and CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV multiplex respiratory test.
Pediatric influenza and Mycoplasma pneumoniae infections returned to pre-pandemic levels after COVID-19 restrictions were lifted.
A study shows that a loss of immunity caused flu and RSV peaks to occur earlier in the season before returning to pre-pandemic patterns.
Specific host genotypes and sexes can cause influenza A viruses to gain virulence faster, potentially impacting the severity of flu outbreaks.
Enanta Pharma advanced zelicapavir into a registrational Phase 2b/3 clinical trial for adults at high risk of severe RSV outcomes.
Martha Lillard, who was diagnosed with polio at age 5, passed away at the age of 78 after using an iron lung device for over seven decades.